Identification of KIF21A Mutations as a Rare Cause of Congenital Fibrosis of the Extraocular Muscles Type 3 (CFEOM3)

Koki Yamada,1,2 Wai-Man Chan,2 Caroline Andrews,1,2 Thomas M. Bosley,3 Emin C. Sener,4 Joban T. Zwaan,5 Paul B. Mullaney,5 Banu Öztürk,7 A. Nurten Akarsu,7 Louise J. Sabol,8 Joseph L. Demer,9 Timothy J. Sullivan,10 Irene Gottlob,11 Peter Roggenkämper,12 David A. Mackey,13 Clara E. de Uzcategui,14 Nicolas Uzcategui,15 Bruria Ben-Zeet,16 Elias I. Traboulsi,17 Adriano Magli,18 Teresa de Berardinis,18 Vincenzo Gagliardi,18 Sudha Awasthi-Patney,19 Marlene C. Vogel,20 Joseph F. Rizzo III,21 and Elizabeth C. Engle1,2,22

Purpose. Three congenital fibrosis of the extraocular muscles phenotypes (CFEOM1–3) have been identified. Each repre-

From the Departments of 1Genetics and 22Neurology, Children’s Hospital, Boston, Massachusetts; the 2Harvard Medical School, Boston, Massachusetts; the 3Division of Neuro-ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; the 4Department of Ophthalmology, Ankara Gümüş Hospital, Ankara, Turkey; the 5Department of Ophthalmology, University of Texas Health Science Center, San Antonio, Texas; the 6Department of Ophthalmology, Sligo General Hospital, County Sligo, Ireland; the 7Gene Mapping Lab, Pediatric Hematology Unit, Department of Pediatrics, Hacettepe University Medical Faculty, Ankara, Turkey; the 8Department of Ophthalmology, Gei-
singer Medical Institute, Danville, Pennsylvania; the 9Departments of Ophthalmology and Neurology and the Jules Stein Eye Institute, Uni-
versity of California Los Angeles, Los Angeles, California; the 10Royal Children’s Hospital, Department of Ophthalmology, University of Queensland, Brisbane, Australia; the 11Department of Ophthalmology, University of Leicester, Leicester, United Kingdom; the 12University Eye Clinic, Bonn, Germany; the 13University of Melbourne, Department of Ophthalmology, Royal Victorian Eye and Ear Hospital, Melbourne, Australia; 14Instituto de Otorrinolaringología, San Bernardino, Caracas, Venezuela; the 15Children’s Hospital of Los Angeles, Doheny Eye Insti-
tute, University of Southern California, Los Angeles, California; the 16Sheba Medical Center, Sacker School of Medicine, Tel Aviv Univer-
sity, Tel Aviv, Israel; 17Cole Eye Institute, the Cleveland Clinic Foun-
dation, Cleveland, Ohio; 18Dipartimento di Scienze Oftalmologiche, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II” Naples, Italy; the 19KA Institute of Strabismology and Dr. H. L. Patney Memorial Eye Clinic, Rajkot, India; the 20Department of Ophthalmology, Hospital de Niños “Roberto del Rio,” Santiago, Chile; and the 21Department of Ophthalmology, Harvard Medical School and the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. Supported by National Eye Institutes Grants R01-EY12498 and R01-EY15585 to (ECE) and P30-HD18655 to Children’s Hospital Bos-
ton, Mental Retardation Research Center. Submitted for publication December 31, 2003; revised February 12, 2004; accepted March 3, 2004.

Disclosure: K. Yamada, None; W.-M. Chan, None; C. Andrews, None; T.M. Bosley, None; E.C. Sener, None; J.T. Zwaan, None; P.B. Mullaney, None; B.T. Öztürk, None; A.N. Akarsu, None; L.J. Sabol, None; J.L. Demer, None; T.J. Sullivan, None; I. Gottlob, None; P. Roggenkämper, None; D.A. Mackey, None; C.E. de Uzcategui, None; N. Uzcategui, None; B. Ben-Zeev, None; E.L. Traboulsi, None; A. Magli, None; T. de Berardinis, None; V. Gagliardi, None; S. Awasthi-Patney, None; M.C. Vogel, None; J.F. Rizzo III, None; E.C. Engle, None.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact. Corresponding author: Elizabeth C. Engle, Enders 5, Division of Genetics, Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115; engle@enders.tch.harvard.edu.

RESULTS. Twelve CFEOM3 pedigrees and 10 CFEOM3 sporadic individuals were identified in the database. The structures of eight of the pedigrees permitted the generation of meaningful linkage data. KIF21A was screened in 17 probands, and mutations were identified in two CFEOM3 pedigrees. One pedigree harbored a novel mutation (2841G→T, R954W) and the other harbored the most common and recurrent of the CFEOM1 mutations identified previously (2860C→T, R954W). None of CFEOM3 pedigrees or sporadic individuals harbored mutations in PHOX2A.

CONCLUSIONS. The results demonstrate that KIF21A mutations are a rare cause of CFEOM3 and that KIF21A mutations can be nonpenetrant. Although KIF21A is the first gene to be associated with CFEOM3, the results imply that mutations in the unidentified FEOM3 gene are the more common cause of this phenotype. (Invest Ophthalmol Vis Sci. 2004;45:2218–2223) DOI:10.1167/iovs.03-1413

We have defined three congenital fibrosis of the extraocular muscles phenotypes, CFEOM1–3. In each, affected individuals are born with a nonprogressive ophthalmoplegia affecting extraocular muscles primarily in the oculomotor and/or trochlear nerve distribution. We group these three syndromes with the various forms of Duane syndrome, congenital ptosis, congenital facial palsy, and Moebius syndrome as the congenital cranial dysinnervation disorders (CCDDs), a term we recently proposed for disorders we believe result from aberrant innervation of the ocular and facial muscula-

2218

Copyright © Association for Research in Vision and Ophthalmology
ward) and with the inability to raise either above the horizontal midline. The phenotype is quite stereotypic and varies among affected individuals only in the degree of residual normal and aberrant movement within the lower quadrants. Our neuro-pathologic study demonstrated that CFEOM1 results from absence or hypoplasia of the superior division of the oculomotor nerve and corresponding a-motoneurons in the midbrain, with hypoplasia of the levator palpebrae superioris and superior rectus muscles and, presumably, aberrant innervation of other extraocular muscles. 2 CFEOM1 is the most common of the CFEOM phenotypes and is inherited as a fully penetrant autosomal dominant trait. We have demonstrated that in most pedigrees CFEOM1 maps to the FEOM1 locus on chromosome 12cen. 3–6 and results from recurrent heterozygous mutations in a developmental kinesis, KIF21A. 7 Similar to other members of the kinesin superfamily, mouse Kif21a is a motor protein engaged in anterograde axonal transport. 8 We have identified six different pathogenic KIF21A mutations in 44 (98%) of 45 CFEOM1 probands. The KIF21A mutations found in CFEOM1 preferentially alter several conserved amino acid residues within the KIF21A stalk region, and we propose they interfere with KIF21A dimerization. We hypothesize that the mutated KIF21A is unable to carry its unidentified cargo from the oculomotor nucleus motoneurons toward the developing neuromuscular junction of the extraocular muscle and that the cargo is critical to the normal development of these axons. 2 Individuals with CFEOM2 (OMIM 602078) are born with bilateral exotropic ophthalmoplegia and ptosis, with little phenotypic variability. We have identified this recessive disorder in consanguineous pedigrees, mapped it to the FEOM2 locus on 11q13, 9 and shown that it results from homozygous mutations in PHOX2A (ARIX). 10–11 PHOX2A encodes a homeodomain transcription factor essential to the development of the oculomotor and trochlear motoneurons in mice and zebrafish. 12–15 Hence, we propose that these cranial nuclei fail to form in CFEOM2 probands.

Individuals with the third CFEOM phenotype, CFEOM3, are those with CFEOM who do not have CFEOM1 or CFEOM2. This includes, for example, individuals who have unilateral CFEOM, have an orthotropic or hypertropic position in primary gaze, or have a primary gaze that is hypotropic but can be elevated above the midline in either eye. CFEOM3 can be inherited as an autosomal dominant trait, and we have identified families in which all affected individuals have CFEOM3, 14,15 as well as families in which some affected individuals have CFEOM3, and some have CFEOM1. 16 We define a CFEOM1 pedigree as a CFEOM pedigrees in which all affected individuals meet CFEOM1 criteria and a CFEOM3 pedigree as one in which at least one affected individual does not meet CFEOM1 criteria (and the pedigree is not CFEOM2). 7 CFEOM3 pedigrees typically demonstrate broader phenotypic variability than CFEOM1 and CFEOM2 pedigrees, and all contain at least one affected family member with absent or unilateral ptosis, unilateral ophthalmoplegia, noninfraducted primary eye position, and/or the ability to raise at least one globe above the horizontal midline. We have described the linkage analyses of our three large CFEOM3 pedigrees. The phenotype in two maps to a unique locus, FEOM3, on 16qter. 14,16 (OMIM 606838), and the third family’s phenotype maps back to the FEOM1 locus 17 (CFEOM3A; OMIM 607054). The FEOM3 gene has not been identified.

With the identification of KIF21A and PHOX2A as the CFEOM1 and CFEOM2 disease genes, respectively, we are now able to define our CFEOM3 population better. To elucidate the genetic bases of CFEOM3, we identified the CFEOM3 cases in our CCDD database, summarized their clinical phenotypes, determined which CFEOM loci they potentially map to, and screened each pedigree and sporadic case for mutations in both KIF21A and PHOX2A.

Methods
We identified all CFEOM3 index cases in our participant database using the classification scheme just summarized. 5 The study was approved by the Children’s Hospital Boston institutional review board and informed consent was obtained from participants and/or their guardians. Our methods adhered to the Declaration of Helsinki for research involving human subjects.

Each proband and his/her participating family members were examined and donated a blood sample. High-molecular-weight genomic DNA was extracted from each blood sample according to standard procedures. Linkage analysis using fluorescently labeled microsatellite markers spanning the FEOM1, FEOM2, and FEOM3 loci was performed on those pedigrees with sufficient structure. 7 KIF21A mutation analysis was conducted by PCR amplification of the 38 KIF21A exons and flanking intron–exon boundaries from genomic DNA of each proband. The amplicons were subjected to analysis by denaturing high-performance liquid chromatography (DHLPC) using a nucleic acid fragment analysis system (WAVE; Transgenomic, Inc., Omaha, NE) and/or to direct DNA sequencing on an ABI 3100 DNA sequencer (Applied Biosystems, Foster City, CA) as previously described. 7 The PCR sequencing and DHLPC primers and conditions are available on request. The three PHOX2A exons and flanking intron–exon boundaries were similarly amplified using our published primer sets 10 and these amplicons were directly sequenced. Results were compared to normal control individuals. If a mutation was detected in a proband, the participating family members were subsequently screened for the mutation as well.

Results
Phenotype
We identified 12 CFEOM3 pedigrees and 10 sporadic CFEOM3 individuals in our CCDD participant database that met our inclusion criteria; their phenotypes are summarized in Table 1. Of the 12 CFEOM3 pedigrees, at least 6 contained one or more affected members with CFEOM1, and at least 3 contained one or more affected members with unilateral ophthalmoplegia. Although there was marked inter- and intrafamilial variability in primary eye position and severity of vertical movement restriction, hypotropic and exotropic globe positions were observed more frequently than the hypertropic and esotropic positions.

Five of the 10 sporadic CFEOM3 individuals had unilateral disease. Only two of those individuals had ptosis, and in each case the ptosis was ipsilateral to the ophthalmoplegia. Among the five individuals with bilateral ophthalmoplegia, four had bilateral ptosis and one did not. At least two sporadic individuals had an orthotropic primary gaze and one was hypertropic. Most of the sporadic CFEOM3-bearing individuals had absent or severely limited vertical gaze. In contrast, six had normal or only mildly limited horizontal gaze.

Linkage and Haplotype Analysis
The family structures of 8 of the 12 CFEOM3 pedigrees permit the generation of potentially meaningful haplotype data at the FEOM1 and FEOM3 loci (Fig. 1 and Table 1). Of these, we have published the clinical description and linkage analysis of the data in pedigrees BN and DP, which map to the FEOM3 locus, 14,16 and that in pedigree BW, which maps to FEOM1 with 97% penetrance and a maximum lod score of 10.8. 17 Of the 29 affected members of pedigree BW, 18 met CFEOM1 criteria and 11 met those for CFEOM3. The individuals with CFEOM3 had absent ptosis, an orthotropic primary globe position, and/or residual upgaze. Of the five unpublished pedi-
<table>
<thead>
<tr>
<th>Pedigree</th>
<th>Ethnic Origin</th>
<th>Affected/CFEOM3* (n)</th>
<th>Clinical Features that Classify Pedigree as CFEOM3†</th>
<th>FEOM1 Haplotype Analysis</th>
<th>KIF21A Mutation Analysis</th>
<th>FEOM2 Haplotype Analysis</th>
<th>ARIX Mutation Analysis</th>
<th>FEOM3 Haplotype Analysis</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CFEOM3 Pedigrees</td>
<td></td>
<td></td>
<td></td>
<td>L rp</td>
<td>2841G→A</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>17</td>
</tr>
<tr>
<td>BW Turkish 29/11</td>
<td></td>
<td>Absent and unilateral ptosis; orthotropic primary position; elevation above midline</td>
<td>2841G→A</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BE Saudi Arabian 6/6</td>
<td></td>
<td>Slight residual upgaze</td>
<td>CW</td>
<td>2860C→T</td>
<td>N/n</td>
<td>—</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BN French Canadian 16/10</td>
<td></td>
<td>Absent and unilateral ptosis; unilateral ophthalmoplegia; orthotropic primary position; elevation above midline</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DP Australian 15/15</td>
<td></td>
<td>Absent and unilateral ptosis; orthotropic primary gaze</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>L</td>
<td>14,15</td>
</tr>
<tr>
<td>CS Turkish 4/2</td>
<td></td>
<td>Orthotropic primary position</td>
<td>CW rp</td>
<td>None</td>
<td>N/n</td>
<td>None</td>
<td>CW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AT USA-MEA 3/3</td>
<td></td>
<td>Unilateral ophthalmoplegia; residual upgaze</td>
<td>N</td>
<td>—</td>
<td>n</td>
<td>None</td>
<td>CW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BF Saudi Arabian 3/3</td>
<td></td>
<td>Absent ptosis; unilateral ophthalmoplegia</td>
<td>N</td>
<td>—</td>
<td>N/n</td>
<td>None</td>
<td>CW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DR USA-Hispanic 2/2</td>
<td></td>
<td>Exotropic primary position</td>
<td>N</td>
<td>—</td>
<td>CW</td>
<td>None</td>
<td>CW</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BI Australian 2/1</td>
<td></td>
<td>Absent ptosis; orthotropic primary position</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BM Swiss 2/1</td>
<td></td>
<td>Absent ptosis; orthotropic primary position</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DC German 2/1</td>
<td></td>
<td>Absent ptosis; slight residual upgaze</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FI Australian 2/2</td>
<td></td>
<td>Orthotropic primary position; elevation above midline</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFEOM3 Sporadic Individuals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AY USA 1/1</td>
<td></td>
<td>Unilateral CFEOM</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BQ Venezuelan 1/1</td>
<td></td>
<td>Absent ptosis</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BR Venezuelan 1/1</td>
<td></td>
<td>Residual upgaze</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BY Israeli 1/1</td>
<td></td>
<td>Orthotropic primary position</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CN Turkish 1/1</td>
<td></td>
<td>Unilateral CFEOM; orthotropic</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DB USA-UK 1/1</td>
<td></td>
<td>Absent ptosis; unilateral ophthalmoplegia</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DF Italian 1/1</td>
<td></td>
<td>Orthotropic OD</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DZ Indian 1/1</td>
<td></td>
<td>Absent ptosis; unilateral ophthalmoplegia</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FC Chilian 1/1</td>
<td></td>
<td>Unilateral hypertropia; residual upgaze</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GE Italian 1/1</td>
<td></td>
<td>Absent ptosis; unilateral ophthalmoplegia</td>
<td>—</td>
<td>None</td>
<td>n</td>
<td>None</td>
<td>—</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

L, linked; rp, reduced penetrance; cw, consistent with linkage; N, not linked; n, affected individuals do not reduce to homozygosity across the FEOM2 region; —, not done because it is not indicated; MEA, mixed European ancestry.

* Number of affected participants in the pedigree and number of affected participants with CFEOM3 (the remaining affected participants met CFEOM1 criteria).
† These features represent all criteria not met by a given pedigree; one or all may be present in each affected CFEOM3 family member.
The individual indicates participation in the study. Pedigrees BN and DP mapped to the FEOM3 locus, have been published, and are not shown. Pedigree BW has also been published. Note that pedigree BW had three consanguineous loops and III:8 and III:19 represent the same individual.

We screened 17 CFEOM3 probands for mutations in the KIF21A gene, excluding the five pedigrees (BN, DP, AT, BF, and DR) whose phenotypes did not map to FEOM1 and identified mutations in two of the CFEOM3 pedigrees. The affected members of the Turkish pedigree BW, whose phenotype maps to the FEOM1 locus, harbor a novel KIF21A heterozygous 2841G→A transition at the third nucleotide position of codon 947 in exon 20, resulting in a methionine-to-isoleucine substitution (M947I; Fig. 3A). The affected members of the consanguineous Saudi Arabian pedigree BE, whose phenotype is consistent with linkage to FEOM1 and none of the other loci, harbor the most common CFEOM1 mutation, a heterozygous 2860C→T transition in exon 21, leading to an arginine-to-tryptophan substitution (R954W; Fig. 3B). Each mutation segregates with the CFEOM phenotype in each family and, as predicted by haplotype analysis, the mutation was also present in the clinically unaffected family member, BW-II:2. The 2841G→A change was not found on 210 normal control alleles of diverse ethnicities, including 16 alleles in Turkish pedigrees. The 2860C→T mutation has been reported in 32 CFEOM1 probands and established as a pathogenic missense mutation. None of the remaining 15 probands harbors a KIF21A mutation. Of note, a sporadic individual DB carried a rare KIF21A single-nucleotide polymorphism, 3641C→G (P1214R), that we identified earlier in two members of a large CFEOM1 pedigree with the common 2860C→T mutation. To determine whether any cases of CFEOM3 result from mutations in PHOX2A, we sequenced the three coding exons in all probands, except for BW and BE who harbored KIF21A mutations and BN and DP whose phenotypes mapped to FEOM3. No PHOX2A mutations were detected.

**DISCUSSION**

We identified our cohort of CFEOM3 pedigrees and sporadic individuals from our CCDD database and screened them for linkage to the FEOM loci and for mutations in KIF21A and PHOX2A. We identified pathogenic KIF21A missense mutations in 2 (9%) of the 22 CFEOM3 probands in our database, establishing that mutations in KIF21A are a rare cause of CFEOM3 and confirming the genetic heterogeneity of CFEOM3.

Pedigree BW is a large Turkish family whose CFEOM phenotype was strikingly different from the CFEOM1 pedigrees we...
have described, yet the phenotype maps to the *PEOM1* locus.\(^1,7\) Of interest, we found that the affected members of this pedigree harbored a novel 2841G→A mutation in *KIF21A* that alters the third nucleotide position of codon 947 (M947I). We have previously identified CFEOM1 mutations at nucleotide positions 1 and 2 of this codon.\(^7\) We found a heterozygous 2839A→G transition (M947V) at the first nucleotide position in a small CFEOM1 pedigree with only three affected individuals and a heterozygous de novo 2840T→G transversion (M947R) at the second nucleotide position in an individual with sporadic CFEOM1. Both the M947I and the M947V mutations maintain nonpolar aliphatic R groups at codon 947 and are the only disease-causing conservative *KIF21A* amino acid substitutions we have identified. The M947I substitution is also the first *KIF21A* mutation we have detected that results in CFEOM with variable severity and incomplete penetrance. The occurrence of a CFEOM3 rather than CFEOM1 phenotype in pedigree BW may result in part from environmental factors and occurrence of a CFEOM3 rather than CFEOM1 phenotype in CFEOM with variable severity and incomplete penetrance. The CFEOM1 phenotype.\(^1,7\) Therefore, it is possible that mutations in codon 947 or mutations that result in conservative amino acid changes can cause a more variable and milder CFEOM phenotype than *KIF21A* mutations at the other nucleotide positions. Mutation studies of additional CFEOM pedigrees will help to determine whether such phenotype-genotype predictions are possible.

We identified a *KIF21A* mutation in only one additional CFEOM3 pedigree, the Saudi Arabian pedigree BE. Of note, this pedigree harbored the most common CFEOM1 “hotspot” mutation, 2860C→T, found in 32 CFEOM1 families and sporadic cases and accounting for 72% of all *KIF21A* mutation events we have identified to date.\(^7\) In retrospect, we recognize that all six affected members of pedigree BE shared a similar phenotype that resembles CFEOM1 more closely than it resembles the phenotypes found in the affected members of pedigree BW. All six affected family members had bilateral infractured ophthalmoplegia and ptosis. Their degree of infraction was small compared with most CFEOM1 pedigrees, and they are classified as CFEOM3 because they could elevate their eyes slightly above the midline. The ability to elevate their eyes could result from a small degree of residual function of the superior rectus, or possibly from the function of an aberrantly inserted superior oblique or horizontal rectus muscle(s). Additional genetic studies to determine the frequency with which this common *KIF21A* mutation occurs in CFEOM3 individuals, combined with clinical studies documenting the degree of vertical excursion in CFEOM1 individuals harboring *KIF21A* mutations, should help determine whether it would be appropriate to broaden our clinical definition of CFEOM1 to permit a small degree of globe elevation above the horizontal. If this were done, then pedigree BE and sporadic individual BR (in whom we did not identify a *KIF21A* mutation) would be reclassified as CFEOM1.

Combining these new findings with our published data, we have now identified CFEOM1- and CFEOM3-causing mutations in seven nucleotide positions at four distinct amino acid residues within three exons of *KIF21A*. The small number of altered residues enhances the feasibility of cost-effective *KIF21A* mutation detection in patients with CFEOM, despite the large number of *KIF21A* exons. Currently, we screen *KIF21A* exons 8, 20, and 21 before a more exhaustive search of the remaining 35 exons.

None of the CFEOM3 pedigrees or sporadic cases had mutations in the CFEOM2 gene, *PHOX2A*. This is similar to our finding that none of our CFEOM1 cases harbored *PHOX2A* mutations.
mutations, and reinforces CFEOM2 as the sole CFEOM phenotype caused by mutations in this gene.

We did not identify KIF21A or PHOX2A mutations in the remaining 10 CFEOM3 pedigrees or in any of our sporadic CFEOM3 individuals. Two of these CFEOM3 pedigrees were linked to FEOM3, four were consistent with linkage to FEOM3, and four were indeterminate. Therefore, we anticipate that many of these pedigrees and a subset of the sporadic cases harbor mutations in the unidentified FEOM3 gene.

Additional genetic studies, including the identification of FEOM3 and other associated gene(s), will facilitate the molecular genetic-based diagnosis of CFEOM phenotypes and will help us to define better the CFEOM1 and CFEOM3 phenotypes and to determine the feasibility of phenotype-genotype correlations. In addition, future molecular investigations should lead to a better understanding of the selective vulnerability of the oculomotor and/or trochlear motoneuron unit by the mutations in KIF21A, PHOX2A, and the unidentified FEOM3 gene(s).

Acknowledgments

The authors thank all the patients and their families for participating in the study, Rae R. Fellows and Don L. Bremer for referring patients, and Maria P. Rogines-Velo-Sardi and Carlos Miranda for helpful discussions.

References

5. Engle EC, McIntosh N, Yamada K, et al. CFEOM1, the classic familial form of congenital fibrosis of the extraocular muscles, is genetically heterogeneous but does not result from mutations in ARIX. BMC Genet. 2002;3:3.